8LY Stock Chart & Stats
€0.59
-€0.02(-7.82%)
At close: 4:00 PM EST
€0.59
-€0.02(-7.82%)
Day’s Range― - ―
52-Week Range€0.45 - €0.75
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€7.35M
Enterprise Value€79.68
Total Cash (Recent Filing)€935.00K
Total Debt (Recent Filing)€7.50M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.74
Shares Outstanding14,048,068
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-139.70
Price to Sales (P/S)30.78
P/FCF Ratio-6.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)€924.04K
Bulls Say, Bears Say
Bulls Say
Focused Oncology Supportive-Care ProductOncoZenge’s clear product focus on BupiZenge™ for oral mucositis provides a durable strategic asset in a defined clinical niche. A single, clearly targeted therapy simplifies regulatory strategy, clinical development priorities and commercialization planning, sustaining long-term value if clinical/regulatory paths succeed.
Monetization Via Commercialization & PartnershipsThe company’s explicit model—direct commercialization where feasible and out-licensing for other territories—offers durable flexibility. Licensing and milestone/royalty structures can conserve capital, accelerate market access through partners, and reduce execution risk for a small biotech over 2–6 months and beyond.
Positive TTM Gross ProfitPositive gross profit, even at small scale, suggests underlying unit economics for the product can be viable. If revenue growth resumes, fixed-cost leverage could improve margins materially over time. This provides a structural foundation for long-term margin recovery once commercialization expands.
Bears Say
Minimal Revenue, Large Net LossesThe extreme gap between negligible revenue and substantial net losses indicates the company is effectively pre-commercial or failing to monetize at scale. Over several months this undermines self-sufficiency, limits reinvestment capacity, and increases dependence on external funding to maintain development and commercialization timelines.
Heavy And Persistent Cash BurnSustained negative operating and free cash flow signals ongoing funding needs that will likely persist absent clear revenue ramp. This structural cash consumption increases dilution or debt reliance risk, can delay development milestones, and constrains strategic choices over the medium term without new financing.
Very High Leverage And Thin EquityThe shift from equity-funded operations to meaningful debt and extreme leverage materially raises refinancing and covenant risk. With thin equity, the company has limited balance-sheet flexibility; interest and principal obligations could crowd out R&D or commercial investments and heighten insolvency risk if cash generation lags.
OncoZenge AB News
8LY FAQ
What was OncoZenge AB’s price range in the past 12 months?
OncoZenge AB lowest stock price was €0.45 and its highest was €0.75 in the past 12 months.
What is OncoZenge AB’s market cap?
OncoZenge AB’s market cap is €7.35M.
When is OncoZenge AB’s upcoming earnings report date?
OncoZenge AB’s upcoming earnings report date is Aug 27, 2026 which is in 14 days.
How were OncoZenge AB’s earnings last quarter?
OncoZenge AB released its earnings results on May 20, 2026. The company reported -€0.049 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is OncoZenge AB overvalued?
According to Wall Street analysts OncoZenge AB’s price is currently Overvalued.
Does OncoZenge AB pay dividends?
OncoZenge AB does not currently pay dividends.
What is OncoZenge AB’s EPS estimate?
OncoZenge AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does OncoZenge AB have?
OncoZenge AB has 14,048,068 shares outstanding.
What happened to OncoZenge AB’s price movement after its last earnings report?
OncoZenge AB reported an EPS of -€0.049 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.407%.
Which hedge fund is a major shareholder of OncoZenge AB?
Currently, no hedge funds are holding shares in DE:8LY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
OncoZenge AB
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).
Technical Analysis
―
―
Modus Therapeutics Holding AB
―
ExpreS2ion Biotech Holding AB
―
Sprint Bioscience AB
―